Premium
Fusidic acid in dermatology
Author(s) -
Wilkinson Jd
Publication year - 1998
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1998.1390s3037.x
Subject(s) - fusidic acid , impetigo , medicine , acne , dermatology , antibiotics , clindamycin , hidradenitis suppurativa , atopic dermatitis , staphylococcus aureus , mupirocin , seborrhoeic dermatitis , skin infection , staphylococcal scalded skin syndrome , pyoderma , lincomycin , microbiology and biotechnology , biology , methicillin resistant staphylococcus aureus , bacteria , disease , genetics
Fusidic acid is an antibiotic that belongs to a group of its own, the fusidanes. The molecule has a steroid‐like structure but does not possess any steroid activity. The structure is thought to be responsible for the steroid‐like high penetration, and for the fact that no cross‐resistance or cross‐allergy has been seen with other antibiotics in routine clinical use. The anti‐microbial activity of fusidic acid is specifically aimed at the most common skin pathogens, including Staphylococcus aureus , towards which it is one of the most potent antibiotics. The place of fusidic acid in dermatology is in the treatment of mild to moderately severe skin and soft‐tissue infections, e.g. impetigo, folicullitis, erythrasma, furunculosis, abscesses and infected traumatic wounds, whereas it is of less use in conditions such as hidradenitis suppurativa, chronic leg ulcers, burns and pressure sores. The topical combinations of fusidic acid with either betamethasone or hydrocortisone are extremely useful in the treatment of atopic dermatitis/eczema whenever staphylococcal/secondary infection is suspected, and in more persistent cases of eczema where staphylococcal superantigen may be playing an important exacerbating role.